The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists

被引：21

作者：

Porter, David W. ^{[1
]}

Bradley, Michelle ^{[1
]}

Brown, Zarin ^{[1
]}

Canova, Riccardo ^{[2
]}

Charlton, Steven ^{[1
]}

Cox, Brian ^{[1
]}

Hunt, Peter ^{[1
]}

Kolarik, David ^{[2
]}

Lewis, Sarah ^{[1
]}

O'Connor, Des ^{[1
]}

Reilly, John ^{[1
]}

Spanka, Carsten ^{[2
]}

Tedaldi, Lauren ^{[1
]}

Watson, Simon J. ^{[1
]}

Wermuth, Roland ^{[2
]}

Press, Neil J. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England

[2] Novartis Inst BioMed Res, CH-4056 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 01期

关键词：

CXCR2; Chemokines; Pyrazolopyrimidine; Triazolopyrimidine; Neutrophils; COPD; HIT-TO-LEAD; PULMONARY-DISEASE; INTERLEUKIN-8;

D O I：

10.1016/j.bmcl.2013.11.074

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A hit-to-lead optimisation programme was carried out on the Novartis archive screening hit, pyrazolopyrimidine 2-methyl-5-((phenylthio)methyl)pyrazolo[1,5-a]pyrimidin-7-ol 1, resulting in the discovery of CXCR2 receptor antagonist 2-benzyl-5-(((2,3-difluorophenyl)thio)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 14. The SAR was investigated by systematic variation of the pendant thiol, alkyl and pyrimidinol groups. Replacement of the pyrazolopyrimidine core with a triazolo alternative led to a dual series of antagonists with favourable biological and pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：72 / 76

页数：5

共 50 条

[11] Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists
Biswas, Kaustav
Peterkin, Tanya A. N.
Bryan, Marian C.
Arik, Leyla
Lehto, Sonya G.
Sun, Hong
Hsieh, Feng-Yin
Xu, Cen
Fremeau, Robert T.
Allen, Jennifer R.
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (20) : 7232 - 7246
[12] ORGN 54-Discovery of potent, selective, and orally bioavailable antagonists of CC Chemokine Receptor 2
Carter, Percy H.
Brown, Gregory D.
Nelson, David J.
Cherney, Robert J.
Duncia, John V.
Santella, Joseph B., III
Gardner, Daniel S.
Cvijic, Mary Ellen
Mandlekar, Sandhya
Tebben, Andrew J.
Zhao, Qihong
Decicco, Carl P.
Barrish, Joel C.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
[13] Discovery of potent, orally bioavailable CCR5 antagonists - 2.
Palani, A
Shapiro, S
Josien, H
Bara, T
Clader, J
Greenlee, W
Tagat, J
Steensma, R
McCombie, S
Neustadt, B
Pushpavanam, P
Chan, TM
Evans, A
Blythin, D
Ganguly, A
Piwinski, J
Dan, N
Baroudy, B
Endres, M
Strizki, J
Vantuno, N
Cox, K
Broske, L
Zhang, X
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U5 - U5
[14] Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist
Hoashi, Yasutaka
Takai, Takafumi
Kosugi, Yohei
Nakashima, Masato
Nakayama, Masaharu
Hirai, Keisuke
Uchikawa, Osamu
Koike, Tatsuki
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (06) : 3059 - 3074
[15] Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy
Dong, Yi
Fu, Rong
Chen, Jiajing
Zhang, Kehui
Ji, Ming
Wang, Mingjin
Jiang, Huimin
Ye, Wei
Hu, Jinping
Li, Yan
Jin, Jing
Chen, Xiaoguang
Xu, Heng
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (22) : 16626 - 16640
[16] Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists
Scott, James S.
Stead, Darren
Barlaam, Bernard
Breed, Jason
Carbajo, Rodrigo J.
Chiarparin, Elisabetta
Cureton, Natalie
Davey, Paul R. J.
Fisher, David I.
Gangl, Eric T.
Grebe, Tyler
Greenwood, Ryan D.
Hande, Sudhir
Hatoum-Mokdad, Holia
Hughes, Samantha J.
Hunt, Thomas A.
Johnson, Tony
Kavanagh, Stefan L.
Klinowska, Teresa C. M.
Larner, Carrie J. B.
Lawson, Mandy
Lister, Andrew S.
Longmire, David
Marden, Stacey
McGuire, Thomas M.
McMillan, Caroline
McMurray, Lindsay
Morrow, Christopher J.
Nissink, J. Willem M.
Moss, Thomas A.
O'Donovan, Daniel H.
Polanski, Radoslaw
Stokes, Stephen
Thakur, Kumar
Trueman, Dawn
Truman, Caroline
Tucker, Michael J.
Wang, Haixia
Whalley, Nicky
Wu, Dedong
Wu, Ye
Yang, Bin
Yang, Wenzhan
JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 2918 - 2945
[17] Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Zhu, Chenyu
Ze, Shuyin
Zhou, Ronghui
Yang, Xinyu
Wang, Haojie
Chai, Xiaolei
Fang, Meimiao
Liu, Mingyao
Wang, Yonghui
Lu, Weiqiang
Xie, Qiong
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 4734 - 4754
[18] The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists
Bell, Ian M.
Bednar, Rodney A.
Corcoran, Halea A.
Fay, John F.
Gallicchio, Steven N.
Johnston, Victor K.
Hershey, James C.
Miller-Stein, Cynthia M.
Moore, Eric L.
Mosser, Scott D.
Roller, Shane A.
Salvatore, Christopher A.
Theberge, Cory R.
Wong, Bradley K.
Zartman, C. Blair
Kane, Stefanie A.
Williams, Theresa M.
Graham, Samuel L.
Vacca, Joseph P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4740 - 4742
[19] Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes
Xu, Guozhang
Gaul, Michael D.
Song, Fengbin
Du, Fuyong
Liang, Yin
DesJarlais, Renee L.
DiLoreto, Karen
Shook, Brian
Rentzeperis, Dennis
Santulli, Rosie
Eckardt, Annette
Demarest, Keith
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (20)
[20] Discovery of a potent CXCR2 receptor antagonist for the treatment of inflammatory disorders
Dwyer, Michael P.
Yu, Younong
Chao, Jianping
Aki, Cynthia
Chao, Jianhua
Purakkattle, Biju
Rindgen, Diane
Bond, Richard
Jakway, James
Hipkin, R. William
Fosetta, James
Gonsiorek, Waldemar
Bian, Hong
Fine, Jay
Merritt, J. Robert
Rokosz, Laura L.
Kaiser, Bernd
Li, Ge
Wang, Wei
Stauffer, Tara
Ozgur, Lynne
Taveras, Arthur
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231

← 1 2 3 4 5 →